tradingkey.logo

Evolus Inc

EOLS
6.560USD
-0.620-8.64%
Fechamento 11/07, 16:00ETCotações atrasadas em 15 min
424.87MValor de mercado
PerdaP/L TTM

Mais detalhes de Evolus Inc Empresa

Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology in regulatory development. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins, and injectable dermal fillers.

Informações de Evolus Inc

Código da empresaEOLS
Nome da EmpresaEvolus Inc
Data de listagemFeb 08, 2018
CEOMr. David Moatazedi
Número de funcionários332
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 08
Endereço520 Newport Center Dr Ste 1200
CidadeNEWPORT BEACH
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal92660-7022
Telefone19492844555
Sitehttps://www.evolus.com/
Código da empresaEOLS
Data de listagemFeb 08, 2018
CEOMr. David Moatazedi

Executivos da empresa Evolus Inc

Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Vikram Malik
Mr. Vikram Malik
Independent Chairman of the Board
Independent Chairman of the Board
265.91K
+9.47%
Ms. Tatjana Mitchell
Ms. Tatjana Mitchell
Chief Financial Officer
Chief Financial Officer
104.60K
--
Mrs. Brady Stewart
Mrs. Brady Stewart
Independent Director
Independent Director
81.27K
+58.52%
Mr. David N. Gill
Mr. David N. Gill
Independent Director
Independent Director
33.96K
-14.80%
Ms. Karah Parschauer, J.D.
Ms. Karah Parschauer, J.D.
Independent Director
Independent Director
--
--
Mr. Albert G. White, III
Mr. Albert G. White, III
Independent Director
Independent Director
--
--
Mr. Nareg Sagherian
Mr. Nareg Sagherian
Investor Relations
Investor Relations
--
--
Dr. Rui L. Avelar, M.D.
Dr. Rui L. Avelar, M.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
--
--
Mr. David Moatazedi
Mr. David Moatazedi
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
-100.00%
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Vikram Malik
Mr. Vikram Malik
Independent Chairman of the Board
Independent Chairman of the Board
265.91K
+9.47%
Ms. Tatjana Mitchell
Ms. Tatjana Mitchell
Chief Financial Officer
Chief Financial Officer
104.60K
--
Mrs. Brady Stewart
Mrs. Brady Stewart
Independent Director
Independent Director
81.27K
+58.52%
Mr. David N. Gill
Mr. David N. Gill
Independent Director
Independent Director
33.96K
-14.80%
Ms. Karah Parschauer, J.D.
Ms. Karah Parschauer, J.D.
Independent Director
Independent Director
--
--
Mr. Albert G. White, III
Mr. Albert G. White, III
Independent Director
Independent Director
--
--

Detalhamento da receita

Sem dados
Sem dados
Por Empresa
Por Região
Sem dados

Distribuição de ações

Atualizado em: sáb, 23 de ago
Atualizado em: sáb, 23 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Tang Capital Management, LLC
7.71%
Nantahala Capital Management, LLC
6.48%
Lynch (Timothy Patrick)
6.32%
BlackRock Institutional Trust Company, N.A.
5.63%
The Vanguard Group, Inc.
5.27%
Outro
68.59%
Investidores
Investidores
Proporção
Tang Capital Management, LLC
7.71%
Nantahala Capital Management, LLC
6.48%
Lynch (Timothy Patrick)
6.32%
BlackRock Institutional Trust Company, N.A.
5.63%
The Vanguard Group, Inc.
5.27%
Outro
68.59%
Tipos de investidores
Investidores
Proporção
Hedge Fund
38.18%
Investment Advisor
25.41%
Investment Advisor/Hedge Fund
15.74%
Individual Investor
8.47%
Private Equity
7.59%
Corporation
3.30%
Research Firm
1.99%
Bank and Trust
0.56%
Pension Fund
0.56%

Participação acionária institucional

Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
365
58.53M
90.34%
+162.34K
2025Q2
362
58.85M
90.98%
-2.31M
2025Q1
367
61.71M
95.75%
-6.80M
2024Q4
349
59.00M
93.18%
-8.33M
2024Q3
345
58.57M
92.95%
-9.62M
2024Q2
337
59.72M
95.46%
-6.66M
2024Q1
324
57.99M
95.42%
-6.59M
2023Q4
309
53.87M
93.36%
-7.99M
2023Q3
309
51.63M
90.65%
-8.83M
2023Q2
309
53.08M
93.27%
-5.08M
Ver Mais

Atividade dos acionistas

Nome
Ações detidas
Proporção
Variação
Var. %
Data
Tang Capital Management, LLC
5.00M
7.73%
--
--
Jun 30, 2025
Nantahala Capital Management, LLC
4.20M
6.49%
+546.58K
+14.97%
Jun 30, 2025
Lynch (Timothy Patrick)
4.09M
6.33%
+4.09M
--
Aug 11, 2025
BlackRock Institutional Trust Company, N.A.
3.65M
5.64%
-175.30K
-4.58%
Jun 30, 2025
The Vanguard Group, Inc.
3.31M
5.11%
+84.18K
+2.61%
Jun 30, 2025
Caligan Partners, LP
3.34M
5.17%
+610.82K
+22.36%
Jun 30, 2025
Perceptive Advisors LLC
2.47M
3.83%
-1.65M
-40.06%
Jun 30, 2025
Frazier Life Sciences Management, L.P.
2.44M
3.77%
+2.44M
--
Jun 30, 2025
Medy Tox Inc
2.14M
3.3%
-1.24M
-36.82%
Dec 31, 2024
Soleus Capital Management, L.P.
2.12M
3.28%
+1.04M
+96.36%
Jun 30, 2025
Ver Mais

ETFs Relacionados

Atualizado em: qui, 6 de nov
Atualizado em: qui, 6 de nov
Nome
Proporção
SPDR S&P Pharmaceuticals ETF
0.85%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.64%
iShares U.S. Pharmaceuticals ETF
0.15%
iShares Micro-Cap ETF
0.07%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
iShares Russell 2000 Growth ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
Proshares Ultra Russell 2000
0.01%
Ver Mais
SPDR S&P Pharmaceuticals ETF
Proporção0.85%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporção0.64%
iShares U.S. Pharmaceuticals ETF
Proporção0.15%
iShares Micro-Cap ETF
Proporção0.07%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporção0.06%
ProShares Ultra Nasdaq Biotechnology
Proporção0.04%
Invesco Nasdaq Biotechnology ETF
Proporção0.04%
iShares Russell 2000 Growth ETF
Proporção0.02%
Schwab U.S. Small-Cap ETF
Proporção0.01%
Proshares Ultra Russell 2000
Proporção0.01%

Dividendo

Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados

Desdobramento de ações

Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
KeyAI